Dechert recently secured a victory before the Delaware Supreme Court, representing GlaxoSmithKline in the In Re Zantac (Ranitidine) Litigation.
This appellate proceeding challenged the Delaware Superior Court's denial of defense motions to exclude expert reports claiming that Zantac, containing ranitidine or its generic equivalent, is capable of causing ten types of cancer.
On July 10, 2025, the Delaware Supreme Court reversed the lower court’s ruling, stating that the Superior Court erred by favoring the admissibility of expert testimony. The defendants had objected to the methodologies of the plaintiffs' experts, but the Superior Court deemed these objections as matters for the jury. It cited Delaware’s evidentiary rules as more permissive than federal rules and allowed expert conclusions based on the alleged disease-causing agent rather than the specific product. The Supreme Court disagreed and reversed the decision.
The Dechert team serving as lead national counsel to GlaxoSmithKline in the Zantac matter included litigation partners Mark Cheffo, Lindsey Cohan, Hayden Coleman and Will Sachse.
Read the full decision here.
About Dechert
Dechert is the law firm that helps business leaders lead.
For more than 150 years, we have advised clients on critical issues – from high-stakes litigation to first-in-market transaction structures and complex regulatory matters. Our nearly 1,000 lawyers in commercial centers worldwide are immersed in the key sectors we serve – financial services, private capital, real estate, life sciences and technology.
Dechert delivers unwavering partnership so our clients can achieve unprecedented results.
Related Professionals
Subscribe to Dechert Updates